6
Clinical Trials associated with H5N1 influenza vaccine (whole virion, Vero cell-derived)(Ology Bioservices)An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Pediatric Population Aged 6 Months to 17 Years
The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese pediatric population aged 6 months to 17 years
An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Elderly Population Aged 65 Years and Older
The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese elderly population aged 65 years and older.
A Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years
The purpose of this study is to obtain immunogenicity and safety data of two different dose levels of an H5N1 pandemic influenza vaccine in a healthy Japanese adult population aged 18 to 59 years.
100 Clinical Results associated with H5N1 influenza vaccine (whole virion, Vero cell-derived)(Ology Bioservices)
100 Translational Medicine associated with H5N1 influenza vaccine (whole virion, Vero cell-derived)(Ology Bioservices)
100 Patents (Medical) associated with H5N1 influenza vaccine (whole virion, Vero cell-derived)(Ology Bioservices)
100 Deals associated with H5N1 influenza vaccine (whole virion, Vero cell-derived)(Ology Bioservices)